- Published on
Emergency And Acute Medicine – Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder characterized by the formation of noncaseating granulomas due to accumulation of T lymphocytes and mononuclear phagocytes. These granulomas disrupt normal tissue architecture, leading to organ dysfunction. The lungs are most commonly affected, making respiratory symptoms predominant. Granulomatous tissue can produce angiotensin-converting enzyme (ACE) and activate vitamin D, leading to elevated ACE levels and hypercalcemia. The disease affects individuals worldwide, typically presenting between ages 10 and 40, and is more common in Black populations in the United States.
The exact cause of sarcoidosis remains unclear but is thought to involve an exaggerated cell-mediated immune response to an unidentified antigen, either environmental or self-derived. The disease may involve virtually any organ system, resulting in a wide range of clinical presentations. Constitutional symptoms such as fatigue, fever, and general malaise are common. Pulmonary involvement often presents with dyspnea, cough, chest pain, and occasionally hemoptysis. Skin manifestations occur in about 25% of patients and include erythema nodosum, maculopapular lesions, plaques, and lupus pernio. Ocular involvement, seen in about 20% of patients, may present with uveitis, eye pain, and blurred vision.
Neurologic involvement can include cranial nerve palsies—most commonly facial nerve (CN VII)—as well as seizures or altered mental status. Cardiac sarcoidosis, though less common (approximately 5%), can be serious, presenting with arrhythmias, conduction abnormalities such as AV block, or heart failure due to restrictive cardiomyopathy. Renal manifestations may include nephrolithiasis due to hypercalcemia, and musculoskeletal symptoms often involve polyarthralgias. Classic clinical syndromes include Löfgren syndrome (bilateral hilar lymphadenopathy, erythema nodosum, and arthralgias) and Heerfordt–Waldenström syndrome (fever, uveitis, parotid gland enlargement, and facial nerve palsy).
Diagnosis is based on a combination of clinical presentation, imaging, laboratory findings, and histologic confirmation. Chest radiography is abnormal in approximately 90% of patients and is used to stage pulmonary disease, ranging from bilateral hilar lymphadenopathy (stage I) to pulmonary fibrosis (stage IV). Laboratory findings may include elevated serum ACE levels, hypercalcemia, hypercalciuria, mild liver enzyme abnormalities, and hypergammaglobulinemia. CSF analysis may show lymphocytic predominance in neurosarcoidosis. Definitive diagnosis typically requires biopsy demonstrating noncaseating granulomas, often obtained via bronchoscopy or from accessible skin lesions.
The differential diagnosis includes conditions that also produce granulomas or systemic symptoms, such as tuberculosis and other mycobacterial infections, lymphoma, interstitial lung diseases, HIV, and parathyroid disorders.
Management depends on disease severity. Many patients are asymptomatic or have mild disease that resolves spontaneously, and observation without treatment is appropriate in these cases. Corticosteroids, particularly prednisone, are the mainstay of treatment and are indicated in patients with significant or progressive pulmonary disease (stage II or III), severe ocular involvement, neurologic complications, cardiac involvement, or hypercalcemia. Lower doses are used for mild disease, while higher doses are required for severe manifestations such as neurosarcoidosis. Topical corticosteroids and cycloplegic agents may be used for ocular or cutaneous involvement.
Supportive care includes oxygen therapy for hypoxia and monitoring for cardiac arrhythmias. Patients with significant symptoms, hypoxia, or cardiac involvement may require hospital admission. Most patients can be managed as outpatients with close follow-up.
Long-term management involves multidisciplinary care. Patients should be referred to pulmonology for pulmonary function testing, cardiology for conduction abnormalities, ophthalmology for eye involvement, and rheumatology for ongoing disease management. Regular monitoring is important to assess disease progression and complications, particularly those related to chronic steroid use. Patients should also be advised to limit excessive dietary calcium due to the risk of hypercalcemia.
A key clinical pearl is that sarcoidosis often presents incidentally on chest imaging with bilateral hilar lymphadenopathy. While many cases resolve spontaneously, clinicians must remain vigilant for serious complications involving the eyes, heart, or nervous system. Corticosteroids remain the cornerstone of therapy for symptomatic disease.
Sarcoidosis is a chronic, multisystem inflammatory disorder characterized by the formation of noncaseating granulomas due to accumulation of T lymphocytes and mononuclear phagocytes. These granulomas disrupt normal tissue architecture, leading to organ dysfunction. The lungs are most commonly affected, making respiratory symptoms predominant. Granulomatous tissue can produce angiotensin-converting enzyme (ACE) and activate vitamin D, leading to elevated ACE levels and hypercalcemia. The disease affects individuals worldwide, typically presenting between ages 10 and 40, and is more common in Black populations in the United States.
The exact cause of sarcoidosis remains unclear but is thought to involve an exaggerated cell-mediated immune response to an unidentified antigen, either environmental or self-derived. The disease may involve virtually any organ system, resulting in a wide range of clinical presentations. Constitutional symptoms such as fatigue, fever, and general malaise are common. Pulmonary involvement often presents with dyspnea, cough, chest pain, and occasionally hemoptysis. Skin manifestations occur in about 25% of patients and include erythema nodosum, maculopapular lesions, plaques, and lupus pernio. Ocular involvement, seen in about 20% of patients, may present with uveitis, eye pain, and blurred vision.
Neurologic involvement can include cranial nerve palsies—most commonly facial nerve (CN VII)—as well as seizures or altered mental status. Cardiac sarcoidosis, though less common (approximately 5%), can be serious, presenting with arrhythmias, conduction abnormalities such as AV block, or heart failure due to restrictive cardiomyopathy. Renal manifestations may include nephrolithiasis due to hypercalcemia, and musculoskeletal symptoms often involve polyarthralgias. Classic clinical syndromes include Löfgren syndrome (bilateral hilar lymphadenopathy, erythema nodosum, and arthralgias) and Heerfordt–Waldenström syndrome (fever, uveitis, parotid gland enlargement, and facial nerve palsy).
Diagnosis is based on a combination of clinical presentation, imaging, laboratory findings, and histologic confirmation. Chest radiography is abnormal in approximately 90% of patients and is used to stage pulmonary disease, ranging from bilateral hilar lymphadenopathy (stage I) to pulmonary fibrosis (stage IV). Laboratory findings may include elevated serum ACE levels, hypercalcemia, hypercalciuria, mild liver enzyme abnormalities, and hypergammaglobulinemia. CSF analysis may show lymphocytic predominance in neurosarcoidosis. Definitive diagnosis typically requires biopsy demonstrating noncaseating granulomas, often obtained via bronchoscopy or from accessible skin lesions.
The differential diagnosis includes conditions that also produce granulomas or systemic symptoms, such as tuberculosis and other mycobacterial infections, lymphoma, interstitial lung diseases, HIV, and parathyroid disorders.
Management depends on disease severity. Many patients are asymptomatic or have mild disease that resolves spontaneously, and observation without treatment is appropriate in these cases. Corticosteroids, particularly prednisone, are the mainstay of treatment and are indicated in patients with significant or progressive pulmonary disease (stage II or III), severe ocular involvement, neurologic complications, cardiac involvement, or hypercalcemia. Lower doses are used for mild disease, while higher doses are required for severe manifestations such as neurosarcoidosis. Topical corticosteroids and cycloplegic agents may be used for ocular or cutaneous involvement.
Supportive care includes oxygen therapy for hypoxia and monitoring for cardiac arrhythmias. Patients with significant symptoms, hypoxia, or cardiac involvement may require hospital admission. Most patients can be managed as outpatients with close follow-up.
Long-term management involves multidisciplinary care. Patients should be referred to pulmonology for pulmonary function testing, cardiology for conduction abnormalities, ophthalmology for eye involvement, and rheumatology for ongoing disease management. Regular monitoring is important to assess disease progression and complications, particularly those related to chronic steroid use. Patients should also be advised to limit excessive dietary calcium due to the risk of hypercalcemia.
A key clinical pearl is that sarcoidosis often presents incidentally on chest imaging with bilateral hilar lymphadenopathy. While many cases resolve spontaneously, clinicians must remain vigilant for serious complications involving the eyes, heart, or nervous system. Corticosteroids remain the cornerstone of therapy for symptomatic disease.
0 Comments
